ACAM2000
Vaccine
Evidence outlook
Approved: Smallpox and Mpox
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Weak signal
Also approved (4)
- Prevention of smallpox and mpox in individuals at high risk
- Smallpox vaccine (Extraordinary Use New Drug Submission; Notice of Compliance)
- Active immunization for the prevention of smallpox disease in individuals at high risk; indication expanded to mpox on 2026-04-30
- Smallpox vaccine (licensed for smallpox)
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
VIGIV NCT01158157 · Smallpox and Mpox This was a single-arm, open-label study of 25 participants, with everyone receiving ACAM2000 and no comparator or blinding. Its primary endpoint was the occurrence of vaccine-related adverse events, so the results are descriptive and cannot establish comparative benefit or risk. Registry: NCT01158157 | 3 | Percent of Participants With Adverse Events Related to ACAM2000 Vaccine Administration (Days 0 to 90 post-vaccination) 2012-02-14 | Completed. Key figures are not recorded here; the rationale explains the result. | Weak signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.
Phase 3 (1)
What this study did
Phase 2 (2)
What this study did
What this study did
Phase 4 (1)
What this study did
Appears in other studies (1)
Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.
Phase 3 (1)
What this study did
Competitive landscape
No competitors sharing a mechanism or indication in the current universe.
Upcoming events
No upcoming readouts on record for this asset.